Before the company applied to the FDA for the drug to be approved for obesity, Knudsen and her colleagues 'developed a new methodology to show how [GLP-1] drugs exert their effect on the brain by working on the circumventricular organs and communicating further into the hypothalamus, among other effects.' This was designed to illustrate how GLP-1 worked in 'well- defined neurons in the hypothalamus, in the hindbrain, and in the reward centers.' Their rationale for developing the method was because 'It was very important to show that these medicines work on defined brain circuits and not ones that may be related to psychiatric or cardiovascular side effects, for example' (Nair
The same thing happens to a peptide when it's exposed to harsh conditions like heat, agitation, or even light
[1] Retatrutide combines agonism at the GLP-1, GIP, and glucagon receptors, while Tirzepatide targets only the GLP-1 and GIP receptors
July 2021
Casein protein before bed provides sustained amino acid release during sleep, supporting overnight muscle protein synthesis
Drug Metab Dispos 2010;38:396-404
